학술논문
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer
Document Type
Article
Author
Source
In ESMO Open February 2022 7(1)
Subject
Language
ISSN
2059-7029